ArticleAging and disease2025
Blue Zones, an Analysis of Existing Evidence through a Scoping Review.
Article in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Why Some People Live Past 100: The Role of the Immune System in Centenarians, Semi-Supercentenarians and Supercentenarians.International journal of molecular sciences · 2026Review
- From Bench to Clinic: The 2024 FASEB Scientific Research Conference on NAD Metabolism and Signaling.Molecular medicine (Cambridge, Mass.) · 2025Article
- Perspective: Nutrition Research & Programming in Multicultural Populations: The Fixed-Quality Variable-Type (FQVT) Dietary Intervention.Advances in nutrition (Bethesda, Md.) · 2025Article
- Searching for a Potential Blue Zone in the Nordics: A Study on Differences in Lifestyle and Health in Regions Varying in Longevity in Western Finland.Journal of aging research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
"Blue Zones" refer to geographical regions with a high proportion of centenarians. This review aims to identify and synthesize scientific evidence regarding Blue Zones and their characteristics. A scoping review was conducted following PRISMA-ScR guidelines. Systematic bibliographic searches were performed across major scientific databases up to February 2025. Studies were included if they investigated regions which the authors identified as Blue Zones. Non-naturally occurring Blue Zones were excluded. A narrative synthesis of the evidence was carried out. Sixty-five records were included, identifying ten regions: Ogliastra (Sardinia, Italy), Ikaria (Greece), Cilento (Italy), one municipality in The Netherlands, Menorca (Spain), Okinawa (Japan), Rugao (China), Nicoya (Costa Rica), Martinique/Guadeloupe (French overseas regions in the Caribbean) and Loma Linda (California, United States). Longevity indicators revealed that Ogliastra, Okinawa and Nicoya exhibit higher longevity compared to national averages. Ikaria and Cilento show high life expectancy, the municipality in The Netherlands show a higher proportion of exceptional longevous population than other municipalities, whereas Guadeloupe/Martinique present a higher prevalence of supercentenarian deaths than metropolitan France. Data from Menorca remain inconclusive, and Rugao has fewer centenarians. No studies have been conducted in Loma Linda. Factors associated with longevity include diet, physical activity, climate, genetic factors and geographical isolation. The literature indicates that certain geographical areas demonstrated a higher percentage of centenarians than adjacent areas. While regions such as Okinawa, Ogliastra and Nicoya are well-characterized as Blue Zones, others remain under investigation, and some currently lack sufficient scientific evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.